# Kidney biopsy in very elderly patients: indications, therapeutic impact and complications

Mathilde Fedi, Mickaël Bobot, Julia Torrents, Pierre Gobert, Éric Magnant, Yannick Knefati, David Verhelst, Gaëtan Lebrun, Valérie Masson, Philippe Giaime, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

Mathilde Fedi, Mickaël Bobot, Julia Torrents, Pierre Gobert, Éric Magnant, et al. Kidney biopsy in very elderly patients: indications, therapeutic impact and complications. BMC Nephrology, 2021, 22 (1), pp.362. 10.1186/s12882-021-02559-9. inserm-03474201

HAL Id: inserm-03474201

https://inserm.hal.science/inserm-03474201

Submitted on 10 Dec 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
# Kidney biopsy in very elderly patients: indications, therapeutic impact and complications

Mathilde Fedi¹, Mickaël Bobot¹,<fnref n="2" />, Julia Torrents³, Pierre Gobert⁴, Éric Magnant⁵, Yannick Knefatij⁶, David Verhelst⁷, Gaëtan Lebrun⁸, Valérie Masson⁹, Philippe Giaime¹⁰, Julien Santini¹¹, Stanislas Bataille¹⁰,<fnref n="2" />, Philippe Brunet¹,<fnref n="2" />, Bertrand Dussol¹,<fnref n="2" />, Stéphane Burtey¹,<fnref n="2" />, Julien Mancini¹², Laurent Daniel<fnref n="2" />,³ and Noémie Jourde-Chiche¹,<fnref n="2" />*

**Abstract**

**Background:** Few data is available on the risk/benefit balance of native kidney biopsy (KB) in very elderly patients.

**Methods:** Multicenter retrospective cohort study in the Aix-Marseille area: the results of KB and medical charts of all patients over 85 years biopsied between January 2010 and December 2018 were reviewed.

**Results:** 104 patients were included. Median age was 87 years. Indications for KB were: acute kidney injury (AKI) in 69.2% of patients, nephrotic syndrome (NS) with AKI in 13.5%, NS without AKI in 12.5%, and proteinuria in 4.8%. Median serum creatinine was 262 µmol/L, 21% of patients required dialysis at the time of KB. Significant bleeding occurred in 7 (6.7%) patients, requiring blood cell transfusion in 4 (3.8%), and radiological embolization in 1 (1%). The most frequent pathological diagnoses were: non-diabetic glomerular diseases (29.8%, including pauci-immune crescentic glomerulonephritis in 9.6%), hypertensive nephropathy (27.9%), acute interstitial nephritis (16.3%), renal involvement of hematological malignancy (8.7%), and acute tubular necrosis (6.7%). After KB, 51 (49%) patients received a specific treatment: corticosteroids (41.3%), cyclophosphamide (6.7%), rituximab (6.7%), bortezomib (3.8%), other chemotherapies (3.8%). Median overall survival was 31 months.

**Conclusions:** KB can reveal a diagnosis with therapeutic impact even in very elderly patients. Severe bleeding was not frequent in this cohort, but KB may have not been performed in more vulnerable patients.

**Keywords:** Kidney biopsy, Elderly patient, Advanced age, Acute kidney injury, Nephrotic syndrome, Glomerulonephritis, Pathology, Adverse events, Treatment, Survival

**Introduction**

As life expectancy increases, the proportion of elderly patients with renal diseases raises [1, 2]: the medical care of elderly patients is changing in developed countries [3]. The life expectancy in France in 2019 was 85.6 years for women and 79.7 years for men. The median age of dialysis initiation was 70.9 years in 2018 [4] and 12.9%

of prevalent patients on chronic dialysis were older than 85 years.

Kidney biopsy (KB) is an invasive diagnostic procedure aimed at identifying kidney diseases and guiding treatment to prevent progression to chronic kidney disease and end-stage kidney disease (ESKD). Nowadays, there is consensus of opinion that an age over 60–65 years is not a contraindication to kidney biopsy (KB) [5, 6] but the level of evidence for patients over 80–85 years of age remains low. There is a general reluctance [7] to perform KB in very elderly patients due to the risk of complications

<footnote>*Correspondence: noemie.jourde@ap-hm.fr</footnote>

<footnote n="2">² Aix-Marseille Univ, C2VN, INSERM, INRAE, Marseille, France
Full list of author information is available at the end of the article</footnote>
(mostly bleeding) but these patients may also take full
advantage of optimized therapeutic strategies [8–11].

To evaluate the risk/benefit balance of KB in very
elderly patients, we analyzed the indications, adverse
events and therapeutic impact of KB in a cohort of con-
secutive patients over 85 years of age.

Materials and methods

In this retrospective multicenter cohort study, we ana-
lyzed the medical charts of all patients aged ≥85years
who underwent a native kidney biopsy (KB) in 9 neph-
rology centers from the Aix-Marseille area between 2010
and 2018. The same pathologists (LD and JT), from the
Laboratory of Pathology of the University Hospitals of
Marseille (AP-HM), are in charge of all KB in this area
(550 native KB each year), which allowed the screening
of all cases.

All the procedures followed were in accordance with
the Helsinki Declaration of 1975, as revised in 2000.

The French authority on data protection “Commis-
sion Nationale Informatique et Libertés” (CNIL) author-
ized data collection for this study (authorization number:
2211854).

For each case, clinical information was collected from
the medical chart with the help of the referring nephrolo-
gist. Recorded data included:

* age, gender, history of hypertension, diabetes, pro-
  gressive cancer or cardiovascular disease

* physical examination: blood pressure, edema, body
  mass index, extra-renal symptoms

* laboratory values: serum creatinine, estimated glo-
  merular filtration rate (eGFR) using the MDRD for-
  mula, serum albumin, urine protein/creatinine ratio,
  presence of hematuria

* main indication for KB

- pathological diagnosis

* KB-related adverse events

* therapeutic intervention after KB

* kidney function evolution and date of dialysis initia-
  tion if applicable

* date of the last follow-up and date of death if applica-
  ble.

The following immunological tests were collected when
available: antinuclear antibodies, anti-double-stranded
DNA antibodies, anti-neutrophilic cytoplasmic antibody,
anti-phospholipase A2 receptor (PLA2R) antibodies,
rheumatoid factor, cryoglobulinemia, complement C3
and C4, and serum and urine electrophoresis. Serological
tests for hepatitis B, hepatitis C, syphilis and HIV were
also collected.

Indications for KB were classified as: acute kidney
injury (AKI), nephrotic syndrome (NS), coexisting AKI
and NS, proteinuria without AKI, and chronic kidney
disease (CKD).

AKI was defined, according to the KDIGO guidelines,
as an increase in serum creatinine of at least 26.5 µmol/L
within 48 h, or as an increase in serum creatinine to
× 1.5 time baseline [12]. NS was defined as a proteinu-
ria ≥3.5 g/day with serum albumin <3 g/dL. Significant
proteinuria was defined as a urinary protein/creatinine
ratio ≥ 0.5 g/g.

All KB were analyzed by the same renal pathologists (LD and JT), by light microscopy and immunofluorescence. For light microscopy, araldite-embedded sections were stained with Masson's trichrome and Jones silver impregnation (2 and 0.2 µm sections respectively). For Immunofluorescence, 4 µm frozen sections were incubated with anti-Immunoglobulins, C3, and C1q antibodies (The binding site, 1/50 dilutions, Birmingham, UK).

Descriptive statistics are presented as medians and
interquartile ranges for continuous variables and as abso-
lute values and percentages for categorical variables. The
study endpoints were overall survival (OS) and renal sur-
vival, computed from the date of the biopsy to the date of
the event (all-cause death for OS; all-cause death or dial-
ysis for renal survival) or censored at the date of the last
follow-up in event-free patients. Median survival rates
were estimated using the Kaplan-Meier method. Hazard
ratio were estimated using Cox regression model. All fac-
tors associated with outcomes in the univariate analyses
(*p*-value<0.20) were fed into the multivariable models.
All statistical tests were two-sided and the threshold for
statistical significance was *p* < 0.05. Analyses were per-
formed using IBM SPSS Statistics 20.0 (IBM Inc., New
York, USA).

Results

Between January 2010 and December 2018, a total of 114
very elderly patients underwent a native KB analyzed at
the Laboratory of Pathology of AP-HM, which represents
2% of all native KB analyzed during the same period.
Clinical data collection was insufficient for 10 patients,
and 104 patients were included in this study. Follow-up
data was available for 96 patients, who were considered
in the survival analyses. The baseline characteristics of
the study population are shown in Table 1.

The KB was performed during the course of a hos-
pital stay in 73 patients, while 31 patients were hospi-
talized specifically for KB. The indications for KB are
shown in Fig. 1. AKI was the most common indication
(69.2% of patients), the other indications were NS with
AKI (13.5%), NS without AKI (12.5%) and proteinuria
(4.8%). No patient had a KB for the exploration of CKD
<table><caption>**Table 1** Baseline characteristics of the elderly patients (aged ≥85 years) included in this cohort. (Values are expressed as median [IQR] or number (%))</caption><thead><tr><th></th><th>N = 104</th></tr></thead><tbody><tr><td>Age, years</td><td>87 [86–89]</td></tr><tr><td>Male</td><td>64 (61.5)</td></tr><tr><td>BMI, kg/m2</td><td>25 [21–28]</td></tr><tr><td>Hypertension</td><td>70 (67.3)</td></tr><tr><td>Diabetes mellitus</td><td>24 (23.1)</td></tr><tr><td>Progressive cancer</td><td>26 (25.0)</td></tr><tr><td>Cardiovascular disease</td><td>66 (63.5)</td></tr><tr><td>Serum creatinine, µmol/L</td><td>262 [159–416]</td></tr><tr><td>eGFR, ml/min/1.73 m2</td><td>16 [8–27]</td></tr><tr><td>Dialysis requirement</td><td>22 (21.2)</td></tr><tr><td>UPCR, g/g</td><td>1.4 [0.6–4.00]</td></tr><tr><td>Hematuria</td><td>43 (41.3)</td></tr><tr><td>Serum albumin, g/dL</td><td>28 [21–52.5]</td></tr></tbody></table>

(BMI, body mass index; eGFR, estimated glomerular filtration rate; UPCR Urinary protein to creatinine ratio)

Significant proteinuria was present in 87.5% of patients, abnormal immunological tests in 27%, and extra-renal symptoms (mostly cutaneous lesions) in 17% of patients.

KB-related adverse events occurred in 7/104 (6.7, 95%CI 2.8–13.4) patients and are detailed in Table 2. Four (3.8%) patients required blood transfusion, including one patient for whom a radiological embolization was performed. No death was related to KB.

Pathological results are displayed in Table 3. Non-dietetic glomerular diseases were diagnosed in 31 (29.8%) patients, including 10 (9.6%) with pauci-immune crescentic glomerulonephritis. Hypertensive nephropathy was diagnosed in 29 (27.9%) patients, and was the most frequent diagnostic in patients with proteinuria alone (4/5), as well as in patients with AKI (21/72) and in patients with NS and AKI (4/14). The most frequent diagnoses in patients with NS without AKI were membranous nephropathy (4/13 patients) and amyloidosis (AL or AA, 4/13 patients).

Overall, a disease likely to respond to a specific treatment was identified in 61 patients (58.7, 95%CI 48.6–68.2%): 56.9% (41/72) of patients with AKI, 71.4% (10/14) of patients with NS and AKI, 69.2% (9/13) of patients with NS without AKI, and 20% (1/5) of patients with proteinuria.

A specific therapy was administered to 51 patients (49, 95%CI 39.1–59.0%) following KB (Table 2), among whom: 6 patients with IgA nephropathy (including 3 Henoch-Schönlein purpura), 4 patients with minimal change disease or focal segmental glomerulosclerosis, and 13 patients with acute interstitial nephritis received corticosteroids; 9 patients with pauci-immune crescentic glomerulonephritis were treated with corticosteroids, associated with cyclophosphamide in 7 and with rituximab in 2; 3 patients with membranous nephropathy received rituximab; 1 patient received rituximab for B lymphoma with AL amyloidosis, and another 1 for membrano-proliferative GN; 4 patients received corticosteroids and bortezomib for AL amyloidosis (n = 1),

<figure><img src="image_3.png" /></figure>
<table><caption>**Table 2** Kidney biopsy-related adverse events, and therapeutic impact of kidney biopsy</caption><thead><tr><th></th><th>n (%)</th></tr></thead><tbody><tr><td><strong>KB-related adverse events</strong></td><td><strong>7 (6.7)</strong></td></tr><tr><td>Mild bleeding or lumbar pain</td><td>3 (2.9)</td></tr><tr><td>Bleeding requiring blood transfusion</td><td>3 (2.9)</td></tr><tr><td>Bleeding requiring blood transfusion and radiological embolization</td><td>1 (0.9)</td></tr><tr><td><strong>Therapeutic intervention after KB</strong></td><td><strong>51 (49.0)</strong></td></tr><tr><td>corticosteroids</td><td>43 (41.3)</td></tr><tr><td>IV cyclophosphamide</td><td>7 (6.7)</td></tr><tr><td>rituximab</td><td>7 (6.7)</td></tr><tr><td>bortezomib</td><td>4 (3.8)</td></tr><tr><td>Other chemotherapy</td><td>4 (3.8)</td></tr></tbody></table>

<table><caption>**Table 3** Pathological diagnoses in the 104 native kidney biopsies</caption><thead><tr><th></th><th>n</th><th>(%)</th></tr></thead><tbody><tr><td><strong>Vascular diseases</strong></td><td><strong>33</strong></td><td><strong>(31.7)</strong></td></tr><tr><td>Hypertensive nephropathy</td><td>29</td><td>(27.9)</td></tr><tr><td>Cholesterol embolism</td><td>2</td><td>(1.9)</td></tr><tr><td>Renal Infarction</td><td>1</td><td>(1)</td></tr><tr><td>Scleroderma renal crisis</td><td>1</td><td>(1)</td></tr><tr><td><strong>Tubulo-Interstitial diseases</strong></td><td><strong>25</strong></td><td><strong>(24)</strong></td></tr><tr><td>Acute interstitial nephritis</td><td>17</td><td>(16.3)</td></tr><tr><td>Acute tubular necrosis</td><td>7</td><td>(6.7)</td></tr><tr><td>Nephrocalcinosis</td><td>1</td><td>(1)</td></tr><tr><td><strong>Glomerular diseases</strong></td><td><strong>31</strong></td><td><strong>(29.8)</strong></td></tr><tr><td>Pauci immune crescentic GN</td><td>10</td><td>(9.6)</td></tr><tr><td>Membranous nephropathy</td><td>6</td><td>(5.8)</td></tr><tr><td>IgA nephropathy</td><td>6</td><td>(5.8)</td></tr><tr><td>embrano-proliferative GN</td><td>3</td><td>(2.8)</td></tr><tr><td>Minimal change disease</td><td>2</td><td>(1.9)</td></tr><tr><td>Focal segmental glomerular sclerosis</td><td>2</td><td>(1.9)</td></tr><tr><td>AA amyloidosis</td><td>2</td><td>(1.9)</td></tr><tr><td><strong>Hematological diseases</strong></td><td><strong>9</strong></td><td><strong>(8.7)</strong></td></tr><tr><td>AL amyloidosis</td><td>3</td><td>(2.8)</td></tr><tr><td>Light chain deposition disease</td><td>1</td><td>(1)</td></tr><tr><td>Myeloma cast nephropathy</td><td>2</td><td>(1.9)</td></tr><tr><td>Light chain tubular inclusions (Fanconi)</td><td>1</td><td>(1)</td></tr><tr><td>Leukemia (CMML) with blastic infiltration</td><td>1</td><td>(1)</td></tr><tr><td>Lymphomatous infiltration (NHL)</td><td>1</td><td>(1)</td></tr><tr><td><strong>Diabetic kidney disease</strong></td><td><strong>3</strong></td><td><strong>(2.9)</strong></td></tr><tr><td><strong>Non-contributive biopsy</strong></td><td><strong>3</strong></td><td><strong>(2.9)</strong></td></tr></tbody></table>

GN Glomerulonephritis; CMML Chronic myelomonocytic leukemia; NHL Non-Hodgkin lymphoma

myeloma cast nephropathy (n = 2) or monoclonal Ig light chain-associated Fanconi disease (n = 1).

Follow-up data were available for 96 patients (8 were lost to follow-up), their outcomes are displayed in Fig. 2. Median follow-up was 17 months (IQR 7–34 months), and follow-up ranged from 10 days (death of the patient) to 97 months. Sixteen (17%) patients died within 6 months after KB. Among the 18 patients who were depending on dialysis at the time of KB, 3 recovered and 1 died within 6 months. Among the 78 patients who were not on dialysis at the time of KB, 5 died within a month, 19 had a worsening of kidney function, 26 an improvement of kidney function, and 28 remained stable; 10 additional patients died within 6 months.

Overall survival is shown in Fig. 3A. Median overall survival was 32 months. Renal survival (composite survival: no death and no dialysis) is shown in Fig. 3B. Median renal survival was 19 months. Factors associated with overall and renal survival, by univariate and multivariate analyses, are detailed in Table 1. Bleeding complications of KB and baseline cardiovascular disease were independently associated with impaired overall and renal survival. In addition, vascular kidney disease on KB and baseline eGFR <15 mL/min/1.73m² were independent predictors of impaired renal survival.

Discussion

We report here a large cohort of very elderly patients who underwent a native KB and show that the adverse events were not frequent and that the result of KB led to a specific therapeutic strategy in half of patients. In patients for whom no specific treatment was indicated, KB may have prevented the initiation of a potentially harmful treatment (such as corticosteroids). This work shows that for some patients, even if they are very old, the KB remains a useful procedure with therapeutic implications, especially in case of AKI and/or NS.

In the present cohort, the bleeding risk of KB was significant but not prohibitive (3% requiring transfusion), without KB-related death. The same level of complication was identified in other series of elderly patients [13]. Even if lower rates of adverse events were reported in younger populations [14], several studies from the literature comparing the bleeding risks of KB in patients of different ages showed bleeding rates similar to the present cohort [15, 16]. In previous studies, the baseline serum creatinine level has been reported to predict bleeding complications after KB [15]. Indeed, in the present cohort, all the patients with bleeding complications displayed AKI, and 3/7 were on dialysis. Halimi et al. [17], in a large national French retrospective cohort study published in 2020, reported a major bleeding after native KB in 2765 of 52,138 (5%) patients (blood transfusions:
<figure><img src="image_4.png" /></figure>

5%; angiographic intervention: 0.4%; and nephrectomy: 0.1%). Independent predictors of bleeding in this cohort were gender, frailty index, anemia, and altered kidney function. Advanced age was not an independent risk factor for bleeding in this large cohort.

Although patients were not selected in this retrospective study, an indication bias is likely in these very elderly subjects, as clinicians may have refrained from performing a KB in the frailest patients or in patients with mild kidney involvement. This may explain why a large majority of patients from this cohort displayed AKI. The question of the futility of performing an invasive procedure such as KB in very old patients, whose life expectancy is probably limited, may arise. Yet, although their median age was 87 years, only 16.7% (16/96) of patients died within 6 months after KB. For comparison purposes, the 1-year survival rate for incident patients on dialysis is 68% in France [4].

The diagnostic benefit of KB in the very elderly has been reported before [18, 19]. Moutzouris et al. [20] in an American cohort of 235 patients over 80 years of age, reported a therapeutic impact of KB in 67% of patients, particularly in those with AKI or NS. In the present cohort, the therapeutic impact of KB also depended on

the indication for KB, patients with NS and/or AKI being the most likely to display a treatable condition, compared to patients with proteinuria alone.

AKI is associated with increased morbidity and mortality, especially in elderly subjects: the in-hospital mortality of elderly patients with AKI ranges from 15 to 40% [20–24]. Pre-renal AKI, essentially due to volume depletion, and obstructive renal failure are the most common cause of AKI in elderly patients [23]. Shock, nephrotoxic drugs and rhabdomyolysis are also frequent causes of AKI. But when the clinical context is far from obvious, or when a glomerulonephritis is suspected, a KB may be useful even in elderly patients to guide the therapeutic strategy [24]. In the present cohort, as in other European cohorts [19, 25], AKI was the most common indication for KB in elderly patients. On the contrary, NS was the main indication for KB in different series of elderly patients from Asia (50% of patients aged ≥80 in Japan [26] 69% of patients aged >80 years in China [6]).

Acute interstitial nephritis (AIN) was the second most frequent diagnosis after hypertensive nephropathy in this cohort. Most AIN were immuno-allergic, related to the prescription of proton pump inhibitors, vitamin K antagonist or antibiotics, which are often prescribed in the
<figure><img src="image_5.png" /></figure>

<table><thead><tr><th>Time</th><th>0</th><th>6 months</th><th>1 year</th><th>2 years</th><th>3 years</th><th>4 years</th><th>5 years</th></tr></thead><tbody><tr><th>number at risk</th><td>96</td><td>74</td><td>54</td><td>35</td><td>19</td><td>13</td><td>6</td></tr><tr><th>% surviving patients</th><td>100</td><td>82</td><td>70</td><td>58</td><td>40</td><td>36</td><td>23</td></tr></tbody></table>

<figure><img src="image_6.png" /></figure>

<table><caption>**Fig. 3** Kaplan Meier survival analyses. A) Overall survival. B) Renal survival</caption><thead><tr><th>time</th><th>0</th><th>6 months</th><th>1 year</th><th>2 years</th><th>3 years</th><th>4 years</th><th>5 years</th></tr></thead><tbody><tr><th>number at risk</th><td>96</td><td>52</td><td>39</td><td>24</td><td>14</td><td>10</td><td>4</td></tr><tr><th>% surviving patients</th><td>79</td><td>62</td><td>55</td><td>43</td><td>32</td><td>30</td><td>17</td></tr></tbody></table>
<table><caption>**Table 4** Factors associated with overall survival and renal survival</caption><thead><tr><th rowspan="2">Variable</th><th colspan="4">Univariate analysis</th><th colspan="4">Multivariable analysis</th></tr><tr><th>Hazard ratio</th><th>95%CI inf</th><th>95%CI sup</th><th>p-value</th><th>Hazard ratio</th><th>95%CI inf</th><th>95%CI sup</th><th>p-value</th></tr></thead><tbody><tr><td><strong>Overall Survival</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Gender Male</td><td>1.1</td><td>0.6</td><td>2.0</td><td>0.701</td><td></td><td></td><td></td><td></td></tr><tr><td>Indication for KB: acute kidney injury</td><td>1.7</td><td>0.7</td><td>4.4</td><td>0.243</td><td></td><td></td><td></td><td></td></tr><tr><td>Absence of specific treatment</td><td></td><td></td><td></td><td>0.360</td><td></td><td></td><td></td><td></td></tr><tr><td>Specific treatment other than corticosteroids</td><td>1.6</td><td>0.6</td><td>4.3</td><td>0.323</td><td></td><td></td><td></td><td></td></tr><tr><td>Specific treatment with corticosteroids</td><td>0.8</td><td>0.4</td><td>1.5</td><td>0.467</td><td></td><td></td><td></td><td></td></tr><tr><td>Age above 87 years</td><td>1.0</td><td>0.6</td><td>1.8</td><td>0.958</td><td></td><td></td><td></td><td></td></tr><tr><td>Acute kidney injury</td><td>1.9</td><td>0.6</td><td>6.2</td><td>0.271</td><td></td><td></td><td></td><td></td></tr><tr><td>Nephrotic syndrome</td><td>1.0</td><td>0.6</td><td>1.9</td><td>0.882</td><td></td><td></td><td></td><td></td></tr><tr><td>Proteinuria level</td><td>0.9</td><td>0.5</td><td>1.7</td><td>0.755</td><td></td><td></td><td></td><td></td></tr><tr><td>Glomerular kidney disease</td><td>0.6</td><td>0.3</td><td>1.2</td><td>0.128</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Tubulo-interstitial kidney disease</td><td>0.8</td><td>0.4</td><td>1.7</td><td>0.634</td><td></td><td></td><td></td><td></td></tr><tr><td>Vascular kidney disease</td><td>1.5</td><td>0.8</td><td>2.6</td><td>0.206</td><td></td><td></td><td></td><td></td></tr><tr><td>eGFR &lt; 15 ml/min/1.73 m2 at kidney biopsy</td><td>1.6</td><td>0.9</td><td>2.9</td><td>0.106</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>eGFR &lt; 30 ml/min/1.73 m2 at kidney biopsy</td><td>1.9</td><td>0.9</td><td>4.2</td><td>0.091</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Body mass index &lt; 20 kg/m2</td><td>1.0</td><td>0.3</td><td>3.3</td><td>0.982</td><td></td><td></td><td></td><td></td></tr><tr><td>Serum albumin &lt; 3 g/dL</td><td>0.9</td><td>0.4</td><td>1.8</td><td>0.732</td><td></td><td></td><td></td><td></td></tr><tr><td>Haematuria</td><td>1.3</td><td>0.7</td><td>2.3</td><td>0.358</td><td></td><td></td><td></td><td></td></tr><tr><td>Hospitalized specifically for kidney biopsy</td><td>0.7</td><td>0.4</td><td>1.4</td><td>0.361</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Bleeding complications of kidney biopsy</strong></td><td>2.8</td><td>1.1</td><td>7.3</td><td><strong>0.034</strong></td><td>3.2</td><td>1.2</td><td>8.2</td><td><strong>0.019</strong></td></tr><tr><td>Diabetes</td><td>0.8</td><td>0.4</td><td>1.6</td><td>0.529</td><td></td><td></td><td></td><td></td></tr><tr><td>Hypertension</td><td>0.6</td><td>0.3</td><td>1.1</td><td>0.109</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Current malignancy</td><td>1.2</td><td>0.6</td><td>2.3</td><td>0.657</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Cardiovascular disease</strong></td><td>2.1</td><td>1.1</td><td>4.2</td><td><strong>0.029</strong></td><td>2.2</td><td>1.1</td><td>4.3</td><td><strong>0.024</strong></td></tr><tr><td><strong>Renal Survival</strong></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Gender Male</td><td>1.4</td><td>0.8</td><td>2.4</td><td>0.281</td><td></td><td></td><td></td><td></td></tr><tr><td>Indication for KB: acute kidney injury</td><td>4.2</td><td>1.3</td><td>13.5</td><td><strong>0.016</strong></td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Absence of specific treatment</td><td></td><td></td><td></td><td>0.150</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Specific treatment other than corticosteroids</td><td>1.2</td><td>0.5</td><td>2.9</td><td>0.700</td><td></td><td></td><td></td><td></td></tr><tr><td>Specific treatment with corticosteroids</td><td>0.6</td><td>0.3</td><td>1.1</td><td>0.084</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Age above 87 years</td><td>0.9</td><td>0.5</td><td>1.5</td><td>0.641</td><td></td><td></td><td></td><td></td></tr><tr><td>Acute kidney injury</td><td>3.0</td><td>0.9</td><td>9.7</td><td>0.061</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Nephrotic syndrome</td><td>0.7</td><td>0.4</td><td>1.4</td><td>0.336</td><td></td><td></td><td></td><td></td></tr><tr><td>Proteinuria level</td><td>0.7</td><td>0.4</td><td>1.3</td><td>0.329</td><td></td><td></td><td></td><td></td></tr><tr><td>Glomerular kidney disease</td><td>0.5</td><td>0.3</td><td>1.0</td><td><strong>0.035</strong></td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Tubulo-interstitial kidney disease</td><td>1.1</td><td>0.6</td><td>2.0</td><td>0.731</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Vascular kidney disease</strong></td><td>1.6</td><td>0.9</td><td>2.8</td><td>0.085</td><td>2.1</td><td>1.1</td><td>3.8</td><td><strong>0.020</strong></td></tr><tr><td><strong>eGFR &lt; 15 ml/min/1.73 m2 at kidney biopsy</strong></td><td>2.3</td><td>1.4</td><td>4.0</td><td><strong>0.002</strong></td><td>2.4</td><td>1.3</td><td>4.3</td><td><strong>0.005</strong></td></tr><tr><td>eGFR &lt; 30 ml/min/1.73 m2 at kidney biopsy</td><td>1.8</td><td>0.9</td><td>3.7</td><td>0.080</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Body mass index &lt; 20 kg/m2</td><td>1.3</td><td>0.4</td><td>4.4</td><td>0.655</td><td></td><td></td><td></td><td></td></tr></tbody></table>
<table><caption>**Table 4** (continued)</caption><thead><tr><th rowspan="2">Univariate analysis<br>Variable</th><th colspan="4">Univariate analysis</th><th colspan="4">Multivariable analysis</th></tr><tr><th>Hazard ratio</th><th>95%CI inf</th><th>95%CI sup</th><th>p-value</th><th>Hazard ratio</th><th>95%CI inf</th><th>95%CI sup</th><th>p-value</th></tr></thead><tbody><tr><td>Serum albumin &lt; 3 g/dL</td><td>0.8</td><td>0.4</td><td>1.5</td><td>0.442</td><td></td><td></td><td></td><td></td></tr><tr><td>Haematuria</td><td>0.9</td><td>0.5</td><td>1.6</td><td>0.764</td><td></td><td></td><td></td><td></td></tr><tr><td>Hospitalized specifically for kidney biopsy</td><td>0.6</td><td>0.3</td><td>1.1</td><td>0.111</td><td>NS</td><td></td><td></td><td></td></tr><tr><td><strong>Bleeding complications of kidney biopsy</strong></td><td>4.4</td><td>1.9</td><td>10.2</td><td>0.001</td><td>4.5</td><td>1.9</td><td>10.8</td><td><strong>&lt; 0.001</strong></td></tr><tr><td>Diabetes</td><td>0.7</td><td>0.3</td><td>1.3</td><td>0.205</td><td></td><td></td><td></td><td></td></tr><tr><td>Hypertension</td><td>0.7</td><td>0.4</td><td>1.2</td><td>0.146</td><td>NS</td><td></td><td></td><td></td></tr><tr><td>Current malignancy</td><td>1.1</td><td>0.6</td><td>2.0</td><td>0.713</td><td></td><td></td><td></td><td></td></tr><tr><td><strong>Cardiovascular disease</strong></td><td>2.5</td><td>1.3</td><td>4.6</td><td><strong>0.005</strong></td><td>2.1</td><td>1.1</td><td>3.9</td><td><strong>0.025</strong></td></tr></tbody></table>

NS Not significant in multivariable analysis

elderly. In this condition, KB allows the withdrawal of the drug, and sometimes the prescription of corticosteroids.

Pauci-immune crescentic GN was the third most frequent diagnosis in this cohort. A high frequency of crescentic GN in elderly patients was also reported in several studies from different countries (10% here, 14% in Spain [25] 11% in Japan [26] 13% in Italy [27]). KB is not always required for the diagnostic of ANCA-associated vasculitis. Yet, it can confirm the diagnosis in patients without ANCA or with atypical clinical presentation and indicate the presence of active proliferative lesions likely to benefit from immunosuppressive treatment. Indeed, immunosuppressive therapy can improve kidney function and systemic disease in ANCA-associated vasculitis, even in elderly patients [28]. In an American cohort of 78 patients over 80 years of age with biopsy-proven pauci-immune GN published in 2011 [9], the use of immunosuppressive therapy was associated with significantly lower risk of ESKD, death, and the combined outcome of ESKD or death.

KB can also be valuable for the diagnosis of haematological malignancies. In particular, AL amyloidosis without myeloma is not always detected on extra-renal tissue (such as minor salivary glands), and the detection of light chain amyloid deposits in a patient with NS can lead to the initiation of a chemotherapy which was not indicated on haematological parameters only. This was the case for 5 patients with hematological diseases from the present cohort.

There are some limitations to this study, in addition to its retrospective design. First, no data was available on the evaluation of frailty, autonomy and quality of life of the elderly patients included here. Second, no data was gathered on the clinical characteristics and outcomes of elderly patients with AKI and/or NS who were not proposed a KB. This hampers the evaluation of the “right

indications for KB” and of the benefit of KB in the global population of elderly patients.

Yet, the focus of this work on very elderly patients (≥85 years), and the comprehensive analysis of KB indications, results, and therapeutic impact, together with the information on patients’ outcomes, brings new information to the field.

In conclusion, this study provides detailed information on the benefits and risks of KB in a population of very elderly patients in France. The reasonable bleeding risk and the high proportion of pathological diagnoses with a therapeutic impact, especially in patients with AKI and/or NS, pleads for the interest of this invasive procedure in some very elderly patients, irrespective of their age.

**Abbreviation**

AKI: Acute kidney injury; AIN: Acute interstitial nephritis; BMI: Body mass index; CKD: Chronic kidney disease; CMML: Chronic myelomonocytic leukemia; ESKD: End-stage kidney disease; eGFR: Estimated glomerular filtration rate; GN: Glomerulonephritis; KB: Kidney biopsy; NHL: Non-hodgkin lymphoma; NS: Nephrotic syndrome; OS: Overall survival; PU: Proteinuria; UPCR: Urinary protein to creatinine ratio.

**Acknowledgements**

We thank Laurent Samson for his help with the kidney biopsy register.

**Authors’ contributions**

M.F., M.B., S.B., J.M. and N.J.C designed the study. M.F. acquired data, with the substantial help of P.G, E.M, Y.K, D.V, G.L, V.M, P.G, J.S, S.B., P.B and B.D. L.D and J.T. performed the pathological examination of the kidney biopsies. M.F. wrote the first draft of the manuscript. S.B., M.B., J.T. and L.D. assisted in the interpretation of the results. J.M made the statistical analyses and prepared Figs. 3. N.J.C. revised the final manuscript. All authors read and approved the final manuscript.

**Funding**

The authors received no financial support for the research, authorship, and publication of this article.

**Availability of data and materials**

The datasets used and analysed during the current study available from the corresponding author on reasonable request.
# Declarations

## Ethics approval and consent to participate

The French authority on data protection "Commission Nationale Informatique et Libertés" (CNIL) authorized data collection for this study (authorization number: 2211854). The need for informed consent was waived by the Commission Nationale Informatique et Liberté, who analyzed the study application and authorized data collection according to the French legislation, under the autorisation number 2211854.

## Consent for publication

Not Applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

¹AP-HM, University Hospital of la Conception, Nephrology and Kidney Transplant Centre, Marseille, France. ²Aix-Marseille Univ, C2VN, INSERM, INRAE, Marseille, France. ³AP-HM, University Hospital of La Timone, Anatomical Pathology Laboratory, Marseille, France. ⁴Rhône Durance Clinic, Medicine Department Avignon, Avignon, France. ⁵Private Hospital of Provence, Nephrology Department, Aix-en-Provence, France. ⁶Hospital of Sainte Musse, Nephrology Department, Toulon, France. ⁷Hospital Général Henri Duffaut, Nephrology Department, Avignon, France. ⁸Hospital of Aix en Provence, Nephrology Department, Aix-en-Provence, France. ⁹Polyclinic "des fleurs", Nephrology Department, Ollioules, France. ¹⁰Phocaean Institute of Nephrology, Bouchard Clinic, ELSAN, Marseille, France. ¹¹Saint-Joseph Hospital, Nephrology Department, Marseille, France. ¹²Aix Marseille Univ, APHM, Inserm, IRD, SESSTIM, University Hospital of la Timone, BIOSTIC Service, Marseille, France.

Received: 29 March 2021 Accepted: 10 August 2021

Published online: 02 November 2021

## References

1. Rule AD. The association between age and Nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010;152:561.

2. Nie P, Chen R, Luo M, Dong C, Chen L, Liu J, et al. Clinical and pathological analysis of 4910 patients who received renal biopsies at a single Center in Northeast China. Biomed Res Int. 2019;2019:1-9.

3. Aucella F, Corsonello A, Leosco D, Brunori G, Gesualdo L, Antonelli-Incalzi R. Beyond chronic kidney disease: the diagnosis of renal disease in the elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG). J Nephrol. 2019;32:165-76.

4. Le rapport du REIN 2018 est en ligne - Agence de la biomédecine [Internet]. 2020. https://www.agence-biomedecine.fr/IMG/pdf/rapport_rein_2018_v2.pdf.

5. Sevillano AM, Diaz M, Caravaca-Fontán F, Barrios C, Bernis C, Cabrera J, et al. On behalf of the Spanish Group for the Study of Glomerular Diseases (GLOSEN): IgA nephropathy in elderly patients. Clin J Am Soc Nephrol. 2019;14:1183-92.

6. Xiong M, Wang L, Liu X, Yue S, Dong J, Li Y, et al. Kidney Biopsies in Elderly Chinese Patients: A Nationwide Survey PMID: 32362418. https://doi.org/10.1053/j.ajkd.2020.02.438.

7. Luciano RL, Moeckel GW. Update on the native kidney biopsy: Core curriculum 2019. Am J Kidney Dis. 2019;73:404-15.

8. Planchais M, Brilland B, Demiselle J, Besson V, Duveau A, Croué A, et al. Renal biopsy in very elderly patients (over 80 years): clinical presentation, histological diagnosis, and long-term outcome. Int Urol Nephrol. 2020;52:721-9.

9. Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79:757-64.

10. Dhaun N, Bellamy CO, Cattran DC, Kluth DC. Utility of renal biopsy in the clinical management of renal disease. Kidney Int. 2014;85:1039-48.

11. Yoon HE, Shin MJ, Kim YS, Choi BS, Kim BS, Choi YJ, et al. Clinical impact of renal biopsy on outcomes in elderly patients with nephrotic syndrome. Nephron Clin Pract. 2011;117:c20-7.

12. Notice. Kidney Int Suppl 2: 1, 2012.

13. Uezono S, Hara S, Sato Y, Komatsu H, Ikeda N, Shimao Y, et al. Renal biopsy in elderly patients: a clinicopathological analysis. Ren Fail. 2006;28:549-55.

14. Bataille S, Jourde N, Daniel L, Mondain J-R, Faure M, Gobert P, et al. Comparative safety and efficiency of five percutaneous kidney biopsy approaches of native kidneys: a multicenter study. Am J Nephrol. 2012;35:387-93.

15. Whittier WL, Korbet SM. Timing of complications in percutaneous renal biopsy. J Am Soc Nephrol JASN. 2004;15:142-7.

16. Parrish AE. Complications of percutaneous renal biopsy: a review of 37 years' experience. Clin Nephrol. 1992;38:135-41.

17. Halimi J-M, Gatault P, Longuet H, Barbet C, Bisson A, Sautenet B, et al. Major bleeding and risk of death after percutaneous native kidney biopsies: a French nationwide cohort study. Clin J Am Soc Nephrol CJN. 2020;14721219. https://doi.org/10.2215/CJN.14721219.

18. Kitterer D, Gürzing K, Segerer S, Alscher MD, Amann K, Braun N, et al. Diagnostic impact of percutaneous renal biopsy. Clin Nephrol. 2015;84(2015):311-22.

19. Nair R, Bell JM, Walker PD. Renal biopsy in patients aged 80 years and older. Am J Kidney Dis. 2004;44:618-26.

20. Moutzouris D-A, Herlitz L, Appel GB, Markowitz GS, Freudenthal B, Radhakrishnan J, et al. Renal biopsy in the very elderly. Clin J Am Soc Nephrol. 2009;4:1073-82.

21. Li Q, Zhao M, Du J, Wang X. Outcomes of renal function in elderly patients with acute kidney injury. Clin Interv Aging. 2017;12:153-60.

22. Akposso K, Hertig A, Couprie R, Flahaut A, Alberti C, Karras GA, et al. Costa De Beauregard MA, Lahlou a, rondeau E, Sraer JD: acute renal failure in patients over 80 years old: 25-years' experience. Intensive Care Med. 2000;26:400-6.

23. Liu J-Q, Cai G-Y, Liang S, Wang W-L, Wang S-Y, Zhu F-L, et al. Characteristics of and risk factors for death in elderly patients with acute kidney injury: a multicentre retrospective study in China. Postgrad Med J. 2018;94:249-53.

24. Coca SG. Acute kidney injury in elderly persons. Am J Kidney Dis Off J Natl Kidney Found. 2010;56:122-31.

25. Verde E, Quiroga B, Rivera F, López-Gómez JM. Renal biopsy in very elderly patients: data from the Spanish registry of glomerulonephritis. Am J Nephrol. 2012;35:230-7.

26. Yokoyama H, Sugiyama H, Sato H, Taguchi T, Nagata M, Matsuo S, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:903-20.

27. Rollino C, Ferro M, Beltrame G, Quattrocchio G, Massara C, Quarello F, et al. Renal biopsy in patients over 75: 131 cases. Clin Nephrol. 2014;82(2014):225-30.

28. Jefferson JA. Treating elderly patients with ANCA-associated Vasculitis. Clin J Am Soc Nephrol. 2015;10:1110-3.

# Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.